
|Videos|May 9, 2022
Neratinib for Metastatic HER2+ Breast Cancer and Brain Metastases
Oncologists debate the use of neratinib for metastatic HER2+ breast cancer treatment in the context of the HER2CLIMB clinical trial data on tucatinib.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Will Successfully Targeting KRAS Change Pancreatic Cancer Treatment?
2
FDA Grants Priority Review to Dostarlimab in dMMR/MSI-H Rectal Cancer
3
Teclistamab Combo Earns EU Approval in Relapsed/Refractory Multiple Myeloma
4
Novel Fluorescence Imaging Agent May Improve Lung Cancer Surgery
5





















































